News & Publications

July 19, 2022

Entos at the Next Generation Lipid-Based Nanoparticles Delivery Summit

Published by:

Perrin Beatty

June 7, 2022

Press Release: Entos Expands R&D Operations into the US

Published by:

Perrin Beatty

March 3, 2022

Press Release: Entos Announces Senior Leadership Appointments to Executive Team

Published by:

Perrin Beatty

January 5, 2022

Press Release: Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications

Published by:

Perrin Beatty

December 1, 2021

Press Conference: Entos to receive $15.5M from Alberta gov't for Edmonton vaccine manufacturing facility

Published by:

Perrin H Beatty

November 16, 2021

Press Release: BioAlberta Recognizes Entos Pharmaceuticals with 2020 Company of the Year Achievement Award

Published by:

Perrin Beatty

November 15, 2021

Press Release: Entos Enters Agreement with BioMarin to Formulate Product Candidates Incorporating Fusogenix PLVs

Published by:

Perrin Beatty

September 7, 2021

Press Release: Entos’ COVID-19 DNA Vaccine Candidate Approved for Phase 2 Clinical Trial in South Africa

Published by:

Perrin Beatty

July 7, 2021

Press Release: Canadian Companies Entos Pharmaceuticals and Montrium Join Forces to Drive Clinical Innovation

Published by:

Perrin Beatty

May 18, 2021

Press Release: Recruitment Update for the Phase 1 Clinical Trial of Entos’ Made in Canada DNA Vaccine for COVID-19

Published by:

Perrin Beatty

March 18, 2020

Press Release: Entos Pharmaceuticals Is Developing a DNA Vaccine Against COVID-19 Using Its Fusogenix Nanomedicine Platform

Published by:

Entos Pharmaceuticals

December 20, 2019

HICKS ON BIZ: The University of Alberta’s next big thing

Published by:

Graham Hicks

November 1, 2018

Entos Pharmaceuticals joins JLABS San Diego

Published by:

Entos Pharmaceuticals

July 2, 2018

Entos awarded entry into the Merck Invention Accelerator

Published by:

Entos Pharmaceuticals

March 30, 2018

Entos and Oisin Bio Announce Fusogenix License for SENSOlytics™

Published by:

Entos Pharmaceuticals

June 26, 2018

Entos and Oisin Bio Launch OncoSenX: A Spinoff Company Targeting Cancer

Published by:

John D. Lewis, PhD

November 13, 2018

Precision Nanosystems and Entos sign license agreement

Published by:

PRESS RELEASE (Precision NanoSystems)

Entos Pharmaceuticals
‍
33 St James's Square
London, UK, SW1Y 4JS

Unit 4550, 10230 Jasper Avenue
Edmonton, Alberta, Canada
T5J 4P6
‍
3040 Science Park Road
San Diego, CA 92121

General Contact
Tel: 1-800-727-0884
Email: info@entospharma.com

Investor Contact
Email: info@entospharma.com

Media Contact
Email: media@entospharma.com‍‍

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.